Anti-tenascin monoclonal antibody 81C6-I-131

Drug Profile

Anti-tenascin monoclonal antibody 81C6-I-131

Alternative Names: I-131 mAb81c6; Neuradiab

Latest Information Update: 01 Aug 2012

Price : $50

At a glance

  • Originator Duke University Medical Center
  • Developer Bradmer Pharmaceuticals
  • Class Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 30 Jul 2012 Bradmer pharmaceuticals terminates its licence agreement with Duke Univeresity
  • 19 Nov 2008 Efficacy data from 2 phase II trials in newly diagnosed glioblastoma multiforme released by Bradmer
  • 23 Jul 2008 Bradmer Pharmaceuticals initiates enrolment in the GLASS-ART phase III trial for primary glioblastoma multiforme in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top